NEUROANATOMICAL AND PHYSIOLOGICAL studies have demonstrated that two connected groups of neurons within the ventrolateral medulla (VLM) play an important role in the control of respiration and vasomotor tone: a rostral (R) region and a more caudal (C) area. Neurons in the RVLM are involved in respiratory rhythm generation (11, 31) , in maintaining resting sympathetic tone (4, 8, 28, 29) , and in sympatho-respiratory and defense reaction integration (7, 14, 21, 25) . The subset of neurons in the CVLM provides tonic inhibitory inputs to the respiratory-related neuronal network (6, 32) and modifies vasomotor tone via inhibition of the RVLM neurons (1, 2, 5, 8, 13) . The interrelationships between the neuronal networks regulating respiratory and cardiovascular functions, and the neurotransmitters and receptors involved in these interlocking networks, are still largely unknown.
In the CVLM region of most mammals, a prominent group of norepinephrine-containing neurons (the A1 cell group) is found. Norepinephrine, when released at targeted sites, may elicit a variety of ventilatory and cardiovascular effects, depending on the specific region and receptor subtype that is present. The ␣ 2 -adrenergic receptors are widely distributed and are present on both neuronal terminals and cell bodies in the RVLM (15) . Activation of prejunctional ␣ 2 -adrenergic receptors inhibits neurotransmitter release, whereas stimulation of receptors located on neuronal cell bodies mediates hyperpolarization and inhibition of firing rate (16) . Systemic administration of ␣ 2 -adrenergic agonists induces alterations in breathing pattern, such as prolonged and variable expiratory time (TE) intervals (20) .
Recently, the mouse has been used as an experimental animal because of its short gestation time, rapid growth, and the availability of a large number of genetically modified strains that can provide valuable information on the neurochemical mechanisms controlling the respiratory and cardiovascular systems (27) . However, important interspecies differences may exist between mice and the more frequently studied animal models. Thus we sought to determine the respiratory and cardiovascular effects of selective stimulation of the CVLM and RVLM to better characterize the mouse model in relation to other animal models. In addition, we examined the role ␣ 2 -adrenergic receptors play in the function of these medullary centers.
The results showed that in mice, as in most mammalian species that are studied, activation of the RVLM causes an increase in the respiratory drive associated with arterial pressure elevation, but stimulation of CVLM induces the opposite effect. Data from mice indicate, for the first time, that prolongation of expiratory duration caused by CVLM stimulation re-quires the participation of ␣ 2 -adrenergic receptors in the RVLM, whereas the accompanying hypotension is mediated through other inhibitory mechanisms.
MATERIALS AND METHODS
The studies were performed on 26 normotensive C57BL/6 mice (23 Ϯ 3.6 g, mean Ϯ SD). Anesthesia was induced by inhalation of methoxyflurane in air and maintained with urethane (1.0 g/kg iv). The level of anesthesia was assessed every 30 min. Supplemental doses of urethane (0.1 g/kg iv) were administered if noxious paw pinch evoked an increase in arterial blood pressure (BP) or withdrawal reflex. The study protocol was approved by the Case Western Reserve University School of Medicine Institutional Animal Care and Use Committee and was in agreement with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Animals were tracheotomized, vagotomized, and artificially ventilated with oxygen at arterial PCO 2 above the apneic point (PaCO 2 ϭ 34 Ϯ 2.4 Torr, 7.4 Ϯ 0.1 pH). At the end of the studies, 0.2 ml of blood were withdrawn from the carotid artery for measurements of arterial blood gases and pH). Body temperature was maintained at 37°C with a heating lamp. The carotid artery and the external jugular vein were cannulated to measure BP and heart rate (HR) and for the administration of fluids and drugs.
Respiratory output was measured by recording the electromyographic activity of the diaphragm (D EMG ) using bipolar, stainless steel, twisted wires that were implanted via a thoracic incision in the costal portion of the diaphragm. The electrical activity was amplified and filtered (0.1 Hz to 3 kHz, Grass P511K), rectified, and integrated (Paynter filter, time constant ϭ 50 ms) using a moving averager (Charles Ward). The integrated moving average D EMG signal was recorded directly onto the computer for subsequent analysis. Mean (M), systolic (S), and diastolic (D) BP and HR were also recorded.
After instrumentation, mice were placed in a stereotaxic apparatus in a prone position. The occipital bone was removed, and the atlanto-occipital membrane was opened. Bregma and the midline served as stereotaxic zeros for rostrocaudal and lateral coordinates. The intramedullary bilateral microinjections of buffered saline vehicle (10 nl), Lglutamate (0.12 nmol, 10 nl), and SKF-86466 (0.4 nmol, 10 nl) were made simultaneously through glass micropipettes with a tip diameter of 40 m, using a pneumatic pressure system (model PPS-2; Medical Systems, Greenvale, NY). The volume of injectate (10 nl) was calibrated at a controlled duration and pressure. This method was described previously by McCrimmon et al. (24) , but we scaled the method down for use in the mouse. Briefly, the micropipettes were directed to the desired stereotaxic position using the bregma and midline as references. Dorsoventral positioning was achieved by slowly lowering the micropipettes at targeted sites. This method allowed the microinjectate to be consistently administered into the parenchyma of the RVLM or CVLM.
L-Glutamate and SKF-86466 were dissolved in saline, and the pH was adjusted to 7.3. In studies examining the role of the noradrenaline ␣ 2 -adrenoreceptor signaling pathway, microinjections of L-glutamate were made into the CVLM 10 min after microinjections of SKF-86466 into the RVLM.
To localize injection sites, the micropipettes were removed at the end of each experiment, filled with Evans blue dye (2%, 10 nl), and reinserted at the same sites, and the dye was microinjected. Animals were deeply anesthetized with an additional dose of urethane and perfused through the heart with saline (50 ml), followed by 4% paraformaldehyde in 0.1 M phosphate buffer. To identify injection sites, the brain stem was sectioned coronally in 50 m thicknesses, mounted, and stained with 1% neutral red.
In three mice, we used immunohistochemistry to identify tyrosine hydroxylase (TH)-expressing neurons, as previously described (19) . For this purpose, a one-in-five series of 50-mthick sections was exposed for 30 min to PBS-Triton solution containing 3% normal rabbit serum to block nonspecific binding sites. After a further wash, the tissue was placed overnight at room temperature in a primary polyclonal antibody solution (1:500 dilution of rabbit anti-tyrosine hydroxylase in PBS; Incstar). The sections were rinsed, incubated with biotinylated goat anti-rabbit secondary antiserum, and further processed using a standard biotin avidin-peroxidase kit (ABC-elite kit, Vector). The immunoreaction was visualized by incubating the section with 0.02% 3,3Ј-diaminobenzidine containing 0.01% hydrogen peroxide for 6 min. A purpleblack reaction was obtained by adding 40 l of 8% NiCl 2 solution (per 100 ml of 3,3Ј-diaminobenzidine solution) to the peroxidase reaction. The sections were rinsed in PBS and then mounted on gelatin-coated glass slides, stained with neutral red, and coverslipped. Control studies were performed to determine whether the primary or secondary antibodies produced false-positive results. Omission of primary or secondary antibodies resulted in the absence of labeling. Slides were viewed with a Leitz Laborlux S microscope. The image was projected onto a television screen and processed through a video processor, and video copy was used to determine dye distribution. The labeled area was plotted on drawings of sections from the atlas of Franklin and Paxinos (12) .
Data analysis. Integrated diaphragmatic activity was used to determine respiratory timing, as well as inspiratory and expiratory durations. The D EMG , inspiratory time (TI), and TE were analyzed, and respiratory frequency (f, breaths/min), and minute D EMG (D EMG ϫ f) were calculated. To quantify the respiratory response, these parameters were averaged in the control period for 50 consecutive breaths and a minimum of 10 breaths at peak response after microinjection of the vehicle or L-glutamate. In addition, BP and HR were measured in the control period and when peak changes occurred after drug administration. Results obtained before and after microinjection of tested drugs were averaged, and percent changes from the control for each variable were calculated. Means and standard error (SE) of the analyzed variables as percent change from the control were compared, and differences were tested by Student's paired t-test. Criterion for statistical significance was P Ͻ 0.05.
RESULTS
The vehicle microinjections into the RVLM or the CVLM had slight transient or no effect on BP, HR, and respiratory parameters; however, microinjections of Lglutamate induced changes in respiratory output, BP, and HR.
Respiratory and cardiovascular effects of RVLM stimulation. Figure 1 shows a coronal section of the medulla oblongata depicting an actual injection site in the RVLM, in parallel with TH staining. The inset shows an example of the response to bilateral microinjections of L-glutamate into this region. As can be seen, simultaneous bilateral microinjection of L-glutamate into the RVLM elicited an increase in f that was often followed by changes in the amplitude of inspiratory http://jap.physiology.org/ discharge. Initially, during increases in BP, a transient decrease followed by a gradual increase in D EMG occurred. On average, in the 10 mice studied, L-glutamate produced a significant rise in f, from 107 Ϯ 13 to 122 Ϯ 12 breaths/min (23 Ϯ 5%, P Ͻ 0.05; Fig. 2A ). The increase in breathing frequency was mainly due to a reduction of TE; TE decreased from 0.54 Ϯ 0.17 to 0.35 Ϯ 0.15 s (Ϫ20 Ϯ 5%, P Ͻ 0.05; Fig. 2B ). In Fig. 2A) .
Furthermore, RVLM stimulation caused elevation of BP and an increase in HR. In the control period, MBP, SBP, and DBP were 82 Ϯ 4, 90 Ϯ 4, and 72 Ϯ 4 mmHg, respectively, and HR was 548 Ϯ 13 beats/min (means Ϯ SE). After bilateral L-glutamate microinjections, MBP increased to 107 Ϯ 6 (30 Ϯ 6%; Fig. 2C ), SBP to 116 Ϯ 5 (29 Ϯ 5%), DBP to 97 Ϯ 6 mmHg (35 Ϯ 7%), and HR rose to 585 Ϯ 13 beats/min (7 Ϯ 2%; Fig.  2C ). Each of these changes was statistically significant (P Ͻ 0.05).
Microscopic findings of the injection site in the RVLM showed that the cardiorespiratory excitatory area is located in the region that partly includes the ventrolateral portion of the paragigantocellular nucleus and neurons ventral to the compact part of the nucleus ambiguus, including those just beneath the ventral medullary surface. This region, which overlaps with the field in which the epinephrine-containing neurons of the C1 cell group are located, was Ϫ6.48 to Ϫ7.20 mm caudal to bregma, 1.2 mm lateral to midline, and at a depth of 1.7-2.0 mm from the dorsal surface of the medulla oblongata.
Respiratory and cardiovascular effects of CVLM stimulation. Figure 3 shows a coronal section of the medulla oblongata depicting the actual injection site in the CVLM (3A), the injection site in parallel with TH staining (3B), and an example of the effects elicited by bilateral microinjections of L-glutamate (3C). The response to bilateral microinjections of L-glutamate into the CVLM (n ϭ 11) consisted of a decrease in frequency of inspiratory discharge, and, in five of the 11 animals, there was a slight increase in peak D EMG , as shown in this example. On average, L-glutamate microinjected into the CVLM elicited a significant reduction in frequency of inspiratory discharge, which decreased from 93 Ϯ 11 to 52 Ϯ 5 breaths/min (Ϫ38 Ϯ 7%, P Ͻ 0.05; Fig. 4A ). This resulted in a decrease in minute D EMG (Ϫ44 Ϯ 4%, P Ͻ 0.05) without significant changes in peak D EMG (Ϫ3 Ϯ 2%; P Ͼ 0.05; Fig. 4A ). The decrease in frequency was mainly due to prolongation of TE. Expiratory duration increased from 0.54 Ϯ 0.12 to 1.01 Ϯ 0.16 s (122 Ϯ 18%, P Ͻ 0.05; Fig. 4B ). Further- more, TI increased from 0.24 Ϯ 0.02 to 0.34 Ϯ 0.04 s (42 Ϯ 8%, P Ͻ 0.05; Fig. 4B ). Hence, ventilatory depression was due to changes in respiratory timing; the rate of D EMG increase tended to decrease because of prolongation of TI. Decreases in BP and HR after CVLM stimulation were significant. MBP, SBP, and DBP decreased from 80 Ϯ 3 to 54 Ϯ 2 (Ϫ33 Ϯ 3%), from 89 Ϯ 3 to 66 Ϯ 2 (26 Ϯ 3%), and from 70 Ϯ 4 to 43 Ϯ 2 mmHg (37 Ϯ 3%), respectively (P Ͻ 0.05 for all values; Fig. 4C ). Furthermore, there was a slight but significant slowing of HR, decreasing from 623 Ϯ 11 to 575 Ϯ 22 beats/min (Ϫ8 Ϯ 3%, P Ͻ 0.05; Fig. 4C) .
Effects of ␣ 2 -adrenergic receptor blockade on respiratory and cardiovascular changes induced by CVLM stimulation. In a separate group of five mice, we studied the possible role of ␣ 2 -adrenergic mechanisms in respiratory and cardiovascular changes observed with CVLM stimulation by prior microinjection of SKF-86466 (an ␣ 2 -adrenergic receptor blocker) into the RVLM. Administration of SKF-86466 into the RVLM caused a slight transient increase in f (12 Ϯ 6%, P Ͼ 0.05). As can be seen in Fig. 5 , after blockade of ␣ 2 -adrenergic receptors in the RVLM, activation of the CVLM produced insignificant changes in respiratory timing and peak D EMG but induced a decrease in BP and HR comparable to that observed in untreated mice. Thus bilateral microinjections of L-glutamate into the CVLM slightly shortened TE and TI (Ϫ5 Ϯ 13% and Ϫ2 Ϯ 12%, respectively, P Ͼ 0.05; Fig. 5B ), insignificantly increased f and minute D EMG (16 Ϯ 12% and 10 Ϯ 10, respectively, P Ͼ 0.05), and had no significant effect on peak D EMG (Ϫ4 Ϯ 4%, P Ͼ 0.05; Fig. 5A ).
Bilateral microinjection of SKF-86466 into the RVLM caused slight increases in MBP (7 Ϯ 11%, P Ͼ 0.05) and HR (2 Ϯ 10%, P Ͼ 0.05), whereas bilateral stimulation of the CVLM after blockade of ␣ 2 -receptors induced significant decreases in MBP and HR (Ϫ23 Ϯ 3 and Ϫ9 Ϯ 2%, respectively, P Ͻ 0.05; Fig. 5C ) that were comparable to those observed in untreated mice.
Histological analysis of injection sites revealed that, in the mouse, the CVLM inhibitory region is located at the level of the caudal end of the area postrema, extending from the ventral compact portion of the nucleus ambiguus to the ventral medullary surface, medial to the spinal trigeminal tract, and lateral to the lateral tip of the dorsal accessory nucleus of the inferior olive. Noradrenergic neurons of the A 1 cell group are present in this region. The coordinates of the vasodepressor region are 7.32-7.48 mm caudal to the bregma, 1.2-1.3 mm lateral to the midline, and 1.6-1.8 mm from the dorsal surface of the medulla oblongata.
Catecholamine-containing neurons in the ventrolateral medulla oblongata. In mice, as in most mammals, catecholamine-containing neurons in the ventral medulla oblongata form paired longitudinal columns extending from the facial nucleus to the pyramidal decussation. As seen in Fig. 1 , the TH-containing cells that presumably belong to the C1 epinephrine-containing cell group can be found in the RVLM region of the reticular formation. In the CVLM region, caudal to the area postrema and rostral to the pyramidal tract, THexpressing neurons were localized in a group resembling the A1 norepinephrine-containing cell group in the rat (Fig. 3) .
DISCUSSION
This study showed that activation of the RVLM and CVLM in mice elicits both respiratory and cardiovascular responses that are similar to those seen in other mammalian species. Encompassed in these regions are catecholamine-containing neuronal cell groups that are identified by TH immunohistochemistry (19, 22) . The cardiovascular responses elicited from the CVLM have usually been attributed to noncatecholamine pathways, but the respiratory responses to CVLM stimulation have not been previously tested in any species. We found that ␣ 2 -adrenergic mechanisms in the RVLM are required for full expression of respiratory responses from the CVLM of the mouse.
TH, an enzyme that catalyzes the initial rate-limiting step in the catecholamine biosynthetic pathway, can be used as a generic marker to identify catecholamine-containing cells (22) . If TH immunohistochemistry is used alone, staining patterns do not allow differentiation among dopamine-, noradrenaline-, and adrenaline-containing cells. However, on the basis of studies comparing antibodies to TH to dopamine-␤ hydroxylase (DBH, the enzyme that converts dopamine to norepinephrine) and phenylethanolamine-Nmethyl transferase (PNMT, the enzyme that synthesizes epinephrine), the type of catecholamine expressed by various catecholamine cell groups has been well defined (22) . These studies have revealed that TH-immunoreactive neurons in the RVLM are also immunopositive for PNMT and are usually considered to be adrenergic. TH-immunoreactive neurons in the CVLM region (A1 cell group) are DBH positive but PNMT negative and, hence, are noradrenergic cells.
In these studies, the pressure microinjection of Lglutamate was used to evoke responses from localized regions of the ventrolateral aspect of medulla oblongata containing C1 and A1 cell groups. To minimize the limitations of the method employed, the glutamate concentration and volume were carefully limited. The dose used (0.12 nmol/site) was more than 50 times lower than that found to induce depolarization blockade (23) . Furthermore, the volume (10 nl/site) was kept below the range capable of reaching cell groups outside the studied regions of the medulla. Previously, Haxhiu et al. (17) found that the radiolabeled drug (4 nmol/80 nl) administered into the RVLM of the rat had diffused Ͻ1 mm from the site of injection at the time of peak response. In fact, 90% of the total radiolabeled concentration was recorded within 0.6 mm of the center of the target region. The concentration of the drug declined exponentially as a function of the distance, as was expected from simple diffusion. Full recovery of the injected radioactivity occurred, ruling out any significant leakage into the peripheral circulation (17) . Thus it is unlikely that the changes observed after microinjection of drugs into the RVLM or CVLM are due to diffusion of the drugs to distant areas, to local depolarization blockade, or to leakage into the peripheral circulation.
RVLM stimulation caused a rise in f and peak integrated D EMG . In parallel with the respiratory changes, activation of the RVLM caused a concomitant increase in arterial pressure, with a slight but significant acceleration of HR. This cardiorespiratory excitatory area was located rostral to the area postrema, caudal to the facial nucleus, in the region that partially overlaps the ventrolateral portion of the paragigantocellular nucleus, and in the neurons ventral to the compact part of the nucleus ambiguus, including those just beneath the ventral medullary surface. This region contains the neuronal network involved in the generation of respiratory rhythmic activity (11, 31) , sympathetic tone (4, 8, 22, 23) , and sympatho-respiratory integration (7, 14, 25) . Furthermore, this region plays an important role in central chemosensitivity (18, 30) and in mediating vasodepressor effects of centrally acting antihypertensive drugs (10, 17) . Taken together, these results indicate that, as in most mammals, the RVLM of the mouse is a site that participates in respiratory and cardiovascular controls (14, 26, 28, 29, 31, 32) . The speciesrelated similarities in the cardiorespiratory responses to L-glutamate microinjections into the RVLM suggest that the mouse is an acceptable model for future studies in respiratory and cardiovascular control mechanisms.
Activation of the mouse CVLM invariably caused a decrease in breathing frequency and arterial hypotension, similar to results found in rats (6, 32) . Our current findings showed that respiratory depression was entirely due to changes in respiratory timing. This cardiorespiratory depressor region is located at the level of the obex, medial to the spinal trigeminal nucleus, near the caudal lateral reticular nucleus, and ventral to the compact portion of the nucleus ambiguus. As in rats (19, 22) , we found that this region of the mouse medulla oblongata also contains A1 norepinephrine-containing cells.
Recently, using subtype-specific antibodies against the two most prevalent subtypes (A and C) of ␣ 2 -adrenergic receptors in the brain, Guyenet et al. (15) found that RVLM neurons express only ␣ 2A -adrenergic receptor-like immunoreactivity (15) . The ␣ 2A -adrenergic receptors are present on neuronal terminals and on neuronal cell bodies, in which their activation inhibits neurotransmitter release and mediates hyperpolarization and inhibition of firing rates, respectively (16) . We found that blockade of these receptors in the mouse RVLM caused a slight increase in f, with no change in BP or HR, suggesting that these receptors may be tonically activated on respiratory, but not cardiovascular, neurons. Furthermore, blockade of ␣ 2 -adrenergic receptors in the RVLM abolished the effects of CVLM stimulation on respiratory timing.
It has been shown that A1 noradrenergic cells are activated by hypoxic or hypercapnic loading (9, 19) and by baroreceptor inputs (1, 2, 5, 13) . Recently, Bach et al. (3) found that oxygen deprivation induces prolongation of expiratory duration that can be abolished by prior blockade of ␣ 2 -adrenergic receptors. Conceivably, A1 cell group-activation by oxygen deprivation may have participated in the changes of respiratory timing. Furthermore, systemic administration of ␣ 2 -adrenergic receptor agonists induced a highly dysrhythmic pattern of ventilation that was characterized by alternating episodes of tachypnea and slow, irregular breathing patterns, including the disruption of ventilation and prolonged and variable TE intervals (20) . These changes suggest that ␣ 2 -adrenergic receptors may play an important role in the control of central respiratory rhythm, and reflex activation of noradrenaline-containing neurons may lead to respiratory dysrythmias.
Blockade of ␣ 2 -adrenergic receptors in the RVLM did not modify the vasodepressor response observed in CVLM stimulation, suggesting that an independent pathway mediates arterial hypotension. Given the presence of a heavy GABAergic projection from the CVLM to the RVLM, this pathway may be responsible for cardiovascular changes in response to CVLM stimulation, as has been previously suggested by others (5) .
In summary, the results obtained in this study indicate that along the ventrolateral medulla of mice, as in other species, there are two distinct areas that differentially modulate cardiorespiratory outputs. The RVLM region contains neurons that, when activated, increase respiratory activity and sympathetic outflow, and the CVLM region possesses respiratory and sympatho-inhibitory cells. In addition, our results demonstrated that the CVLM has the appropriate connections to produce coordinated changes in arterial pressure and respiratory timing. Furthermore, our data showed, for the first time, that ␣ 2 -adrenergic signal transduction pathways play a major role in respiratory, but not cardiovascular, changes induced by activation of the CVLM.
